ARA 290 for Sarcoidosis and Painful Small Fiber Neuropathy

D.A. Culver, Michael Brines(Northwell Health), Anthony Cerami(Araim Pharmaceuticals (United States)), Jinny Tavee(National Jewish Health), Monique van Velzen(Leiden University Medical Center), D. Bajorunas, Martijn R. Tannemaat(Leiden University Medical Center), Richard Kirk(Children's Medical Center), Albert Dahan(Centre for Human Drug Research), L. Aarts, Ann Dunne(Araim Pharmaceuticals (United States)), Maria Jeziorska(University of Manchester), Rizwan Malik(King Khaled Eye Specialist Hospital), I. Petropoulous
Data Archiving and Networked Services (DANS)
October 31, 2016
Cited by 0

Related Papers

Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k
Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic
|Science|2004|800
Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor
|Proceedings of the National Academy of Sciences|2004|654